- Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
- Revance Announces Closing of Public Offering of Common Stock
- Revance Announces Pricing of Public Offering of Common Stock
- Revance Announces Proposed Public Offering of Common Stock
- Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference
- Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones
- Revance Announces China Market License Agreement with Fosun Pharma for RT002
- Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
- Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics Inc (RVNC:NMQ) closed at 17.69, 6.82% above its 52-week low of 16.56, set on Jan 28, 2019.
16.56Jan 28 201934.55Mar 13 2018
Markit short selling activity
|Market cap||758.45m USD|
|EPS (TTM)||-3.96 |
Data delayed at least 15 minutes, as of Feb 15 2019 21:00 GMT.